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S01. Deep phenotyping and genomic analysis for Behcet’s 
disease
A Coleman1, F McKinley2, A Gough2, N Wheatley2, H Xu3, AJ 
McKnight1.
1Centre for Public Health, Queen’s University of Belfast, 2Behcets 
UK, 3Centre for Experimental Medicine, Queen’s University of 
Belfast.
Behcet’s disease (BD) is a complex, multifactorial rare disease, 
which is poorly understood. Genetic and environmental factors 
contribute to BD, but the process of diagnosis is challenging with 
inconsistent clinical manifestations. A recent survey of individuals 
living with rare disease(s) in Northern Ireland revealed ~50% of 
individuals receive ≥1 misdiagnosis with 1/20 seeing >10 doctors.
Individuals with BD report a range of symptoms, which are 
variable in onset, severity, and frequency for this systemic 
vasculitis. Patients describe prolonged journeys to diagnosis with 
multiple healthcare professionals and medical specialties; there is 
no BD specialist in Northern Ireland. Using invitations via social 
media, voluntary groups, and direct contact we are using surveys 
incorporating micro-narratives, one-to-one semi-structured 
interviews, and focus groups to collect detailed family histories 
and stressor information to help characterise recurrent features in 
patients living with BD and their relatives in Northern Ireland.
BD is most often reported in populations along the Silk Road. 
The highest prevalence is reported in Turkey at 20-420/100,000, 
compared 1.5/100,000 individuals in the UK. Mapping through 
general practitioners revealed a much higher than expected 
prevalence of 12.6/100,000 in the Northern Ireland population. 
Clusters were observed in Co. Down and Co. Antrim and plotted 
with social-demographic information. This high ‘UK’ prevalence 
and the identification of several families with multiple members 
diagnosed makes NI ideal to explore genetic and epigenetic risk 
factors for BD.
This project involves deep phenotyping and strategies to improve 
recognition of Behcet’s disease, build collaborative partnerships, 
improve data collection, enhance training, and information sharing.
S02. Capturing Irish Rare Disease activity, a must for improved 
cross border care and research
DM Lambert1, SA Lynch1, R Marron1, D Gray2, EP Treacy1.
1National Rare Disease Office, Mater Misericordiae Hospital, 
Dublin 7, 2National Clinical Programme for Rare Diseases, RCPI.
The National Rare Disease Office (NRDO), initiated in June 2015, 
collates and disseminates Irish rare disease (RD) information.  The 
prevalent nature of RD (1 in 16 of the population, approximately 
80% of which has a genetic basis) and the burden to the health care 
system is under-recognised and a neglected public health issue. 
Awareness of rare diseases is a challenge, especially for GPs who 
each care for > 90 RD patients.
The NRDO has made 58 presentations, lectures and publications 
and received numerous enquiries (58% of contacts from patients/ 
families, 25% from health care professionals and 4% researchers). 
Mapping Irish RD clinical and research expertise is developing 
through Orphanet Ireland. Enrolment of clinical expert centres 
has increased by 50%,but only <10% of the most prevalent RDs 
are represented. This reflects well-developed services for some 
conditions, (e.g. vasculitis and ALS), but more disparate services 
for others (intellectual disability and multisystemic RD). A lack of 
coding and/or registries makes it difficult to identify rare patients 
within hospital systems. Numerous cross-border initiatives seek to 
maximize clinical and research outcomes through collaboration. 
However, < 1% of Irish RD research and <30% of RD clinical 
trials are registered on Orphanet.  For European recognition and 
participation, Ireland must make its RD research visible, and ‘count’ 
RD patients and activity. Irish patients will be disadvantaged unless 
we develop systems to prepare for entry to European Reference 
Networks and become “trial ready”. While progress is slow, these 
are early days and we are optimistic about future developments.
S03. PTEN Hamartoma Tumour Syndrome Screening Audit – 
Northern Ireland 2016
RS Moore1, V McConnell1.
1Clinical Genetics Department, Belfast City Hospital, 51 Lisburn 
Road, Belfast BT9 7AB.
Aims: To assess the tumour surveillance advice given to patients 
in Northern Ireland with confirmed PTEN hamartoma tumour 
syndrome (HTS).
Methods: We used the surveillance advice laid out by the Pan 
Thames Cancer Genetics Group in 2014 to benchmark our 
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patients against. A coding search was carried out on our regional 
information management system to identify all patients with a 
confirmed diagnosis. The written/ electronic notes of these patients 
were reviewed.  We adhered to the National PTEN audit inclusion 
criteria of including patients older than16 years, those with a 
pathogenic/likely pathogenic PTEN mutation or at 50% risk and 
those who had received advice between 01/08/10 - 01/08/2015.
Results: 21 patients were identified. All patients had a pathogenic 
PTEN mutation. 6 children were excluded. 1 adult was excluded 
due to lack of documented advice. 6 patients had a cancer diagnosis. 
9 patients had a positive family history of cancer. Annual breast 
screening was recommended for 67% of patients which involved 
mammography in 83% and MRI in 17%. Annual thyroid USS and 
TFTs were recommended for 54% and 31% of patients respectively. 
16% of female patients had gynaecology referrals completed. 
An annual dermatological review was recommended for 23% of 
patients. Widely variable colonoscopy and renal USS screening 
was recommended for 77% and 65% of patients respectively. No 
cases of Lhermitte-Duclos disease were identified vs 12% in the 
national UK audit.
Conclusions: There is a need for regional PTEN tumour 
surveillance guidelines to be produced and implemented through a 
regional PTEN specialist clinic.
S04. Post-mortem examination of an aggressive case of 
medullary thyroid carcinoma characterized by catastrophic 
genomic abnormalities  
D Kelly1,2*, S Das3,4*, B Moran3,4*, K Han2,5, N Mulligan2,5, C 
Barrett2,5, PG Buckley6, P Mc Mahon1,2, J McCaffrey1,2, HF Van 
Essen7, K Connor3,4, B Ylstra7, D Lambrechts8, WM Gallagher3, 
DP O’Connor3,4§, CM Kelly1,2§  *Equal Contribution, § Senior co-
authors.
1Department of Medical Oncology, Mater Misericordiae 
University Hospital, Eccles St. Dublin 7. 2Conway Institute, 
University Hospital Dublin, Belfield, Dublin 4, Ireland. 3Cancer 
Biology and Therapeutics lab, Conway Institute, University 
College Dublin, Belfield, Dublin 4, Ireland.4 Department of 
Molecular and Cellular Therapeutics, Royal College of Surgeons 
in Ireland, 123 St. Stephens Green, Dublin 2, Ireland. 5Department 
of cellular pathology, Mater Misericordiae University Hospital, 
Eccles St., Dublin.6Molecular Pathology Laboratory, Clinical 
Directorate of Laboratory Medicine, Beaumont Hospital, Dublin 
9, Ireland.7Department of Pathology, VU University Medical 
Center, 1007 MB Amsterdam, The Netherlands. 8Laboratory of 
Translational Genetics, Versailus Research Center, VIB, K.U., 
Leuven, Belgium.
Catastrophic genomic alterations can drive unusually aggressive 
cancer phenotypes. We describe a diagnostically challenging 
rapidly fatal case of medullary thyroid carcinoma (MTC) occurring 
in a young, morbidly obese man presenting with diffuse bone 
marrow involvement and disseminated intravascular coagulation. 
Whole-exome sequencing and shallow whole-genome sequencing 
was carried out for the primary tumour and multiple metastases. 
We identified three germline SNP’s within the RET proto-oncogene 
which remained undetected using routine hospital genetic testing 
procedures. Indeed, one of the variants identified (L769L) has been 
previously reported in literature to be associated aggressive MTC 
presentation, yet remains untested for in the routine diagnosis 
of MTC. Supported by findings from shallow whole genome 
sequencing, we report for the first time in thyroid cancer, the 
occurrence of a catastrophic “chromothripsis-like pattern” (CTLP) 
event, which involved shattering of chromosome 4 leading to 
complete abrogation of normal chromosomal function, in addition 
to dramatic wide-spread copy number aberrations (CNA), across 
both primary tumour and bone marrow samples. We further 
describe the presence of loss-of-heterozygosity (LOH) in key genes 
involved in DNA repair mechanism pathways such as ATM, which 
possibly facilitated the CTLP event, in addition to LOH in other 
disease-associated genes such as ALK and NOTCH1 as key drivers 
of the aggressive and rapidly fatal clinical course in this patient and 
unresponsiveness to the standard-of-care targeted agent chosen. 
Given a possible rapid generation of tumor neo-antigens as a result 
of the CTLP event, immunotherapy may have been more suitable 
as a treatment option. Moreover, the presence of disease-associated 
SNP’s within the RET proto-oncogene, support their inclusion as 
part of routine RET genetic testing for aggressive MTC cases. 
These results provide a rationale for application of comprehensive 
genomic analysis of cancers presenting with unusually aggressive 
behavior to facilitate more appropriate therapeutic options and 
diagnoses.
S05. Target 5000: Genetic characterisation of a cohort of 
inherited retinal degeneration (IRD) patients
A Dockery1, M Carrigan1, C Malone2, D Keegan3, K Stevenson3, 
J Silvestri4, A Green5, J McCourt6, P Humphries1, PF Kenna1,2, GJ 
Farrar1.
1The School of Genetics & Microbiology, Trinity College Dublin, 
Dublin 2, Ireland, 2Royal Victoria Eye and Ear Hospital, Dublin 
2, Ireland, 3The Mater Misericordiae Hospital, Dublin 7, Ireland, 
4The Royal Victoria Hospital, Belfast, Northern Ireland, 5Our 
Lady’s Children’s Hospital, Crumlin, Dublin, Ireland, 6RCSI 
Clinical Research Centre, Smurfit Building, Beaumont Hospital, 
Beaumont Road, Dublin 9, Ireland.
The Target 5000 research project aims to provide genetic testing 
for the estimated 5,000 people in Ireland who have an inherited 
retinal condition. Many clinical trials are available for patients 
with sight loss, however, many such trials require patients to 
have their causative mutation identified in order to enter the trial. 
The objective of the study is to genetically characterise patients 
with inherited retinal degenerations (IRDs) in Ireland and in 
principle to make clinical trials more accessible to some Irish 
people suffering from sight loss. The study also seeks to identify 
previously undiscovered pathological mutations in a panel of 
known retinopathy genes evaluated utilizing target capture next 
generation sequencing (NGS).
Thus far in the study, as part of Target 5000 roughly 10% of the 
Irish IRD population has been sequenced and the results obtained 
are encouraging. Target 5000 offers not only a chance to discover 
new causative mutations, but is vital in giving patients access to 
information regarding the pathogenesis of their disease. Over 50 
novel mutations have been discovered, as well as some previously 
ambiguous phenotypes resolved. More precise matching of 
genotype with phenotype from this study and similar studies 
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globally should start to enable clinicians to better formulate 
accurate future diagnoses and at times prognoses.
S06. Methylation quantitation trait loci and transcriptome 
analysis of differentially methylated microRNAs in end-stage 
renal disease
LJ Smyth1, CE Neville1, GJ McKay1, AP Maxwell1,2, JV Woodside1, 
AJ McKnight1.
1Centre for Public Health, Queen’s University of Belfast, United 
Kingdom, 2Regional Nephrology Unit, Belfast City Hospital, 
United Kingdom
MicroRNAs are understood to play a functional role within the 
establishment of epigenetic marks and are in turn under epigenetic 
control. Emerging evidence suggests microRNAs are vital for 
both kidney development and renal function. This study aimed to 
identify differential methylation affecting microRNAs in patients 
with end-stage renal disease (ESRD).
Methylation status was determined for 485,577 unique CpG 
sites in 105 individuals with ESRD and 52 donor controls with 
no evidence of renal disease using the HumanMethylation450K 
BeadChip array (Illumina). Statistically significant associations 
(P<10-8) were observed between case and control groups for 
both unique CpG sites within microRNAs and their target genes, 
identified using miRDB (an online database for microRNA target 
prediction and functional annotations).
CpG sites (n=11) within top-ranked microRNAs (n=42) alongside 
848 CpGs in 198 target genes were evaluated in genotyped renal 
transplant samples to detect methylation quantitative trait loci 
(meQTLs) associated with ESRD. Following allelic association 
PLINK analysis, 116 SNPs were determined from the investigated 
CpG sites, 12 of which were located in genes previously linked 
with renal disease or microRNAs.
Blood-derived Ion Total RNA-Seq v2 analysis was performed 
on10ESRD samples and 29 controls (with no evidence of renal 
disease)to determine the expression levels of the microRNAs and 
target genes. Sequencing was completed using the Ion Proton™ 
(Thermo Fisher Scientific) and the most significant results 
wereMIR548H4 (5.79x10-6) and WASF3 (5.59x10-9) respectively, 
showing increased expression within the ESRD samples.
This study has identified microRNA-related differential 
methylation with supporting gene expression data, associated with 
ESRD.
S07. Genetic overlap between amyotrophic lateral sclerosis 
and schizophrenia
RL McLaughlin1,2, D Schijven3,4, W van Rheenen3, KR van Eijk3, 
M O’Brien1, Project MinE GWAS Consortium‡, Schizophrenia 
Working Group of the Psychiatric Genomics Consortium, R Kahn4, 
RA Ophoff4,5,6, A Goris7,8, DG Bradley2, A Al-Chalabi9, LH van den 
Berg3, JJ Luykx3,4,10, O Hardiman2, JH Veldink3.
1Academic Unit of Neurology, Trinity Biomedical Sciences 
Institute, Trinity College Dublin, Dublin, Republic of Ireland, 
2 Smurfit Institute of Genetics, Trinity College Dublin, Dublin, 
Republic of Ireland, 3Department of Neurology and Neurosurgery, 
Brain Center Rudolf Magnus, University Medical Center Utrecht, 
Utrecht, The Netherlands, 4Department of Psychiatry, Brain Center 
Rudolf Magnus, University Medical Center Utrecht, Utrecht, 
The Netherlands, 5Department of Human Genetics, David Geffen 
School of Medicine, University of California, Los Angeles, CA, 
US, 6Center for Neurobehavioral Genetics, Semel Institute for 
Neuroscience and Human Behavior, University of California, 
Los Angeles, CA, USA, 7KU Leuven - University of Leuven, 
Department of Neurosciences, Experimental Neurology and 
Leuven Research Institute for Neuroscience and Disease (LIND), 
B-3000 Leuven, Belgium, 8VIB, Vesalius Research Center, 
Laboratory of Neurobiology, B-3000 Leuven, Belgium, 9Maurice 
Wohl Clinical Neuroscience Institute, King’s College London, 
Department of Basic and Clinical Neuroscience, London, United 
Kingdom, 10Department of Psychiatry, Hospital Network Antwerp 
(ZNA) Stuivenberg and Sint Erasmus, Antwerp, Belgium.
Amyotrophic lateral sclerosis (ALS) is a complex neurodegenerative 
disease characterized by rapid-onset loss of upper and lower 
motor neurones, resulting in progressive paralysis and death from 
respiratory failure. Schizophrenia is a neuropsychiatric disease 
with positive symptoms, negative symptoms and impairment 
over a range of cognitive abilities. We have recently shown that 
schizophrenia occurs more frequently than expected in the pedigrees 
of ALS patients, suggesting an aetiological relationship between 
both diseases. Using linkage disequilibrium score regression 
with summary statistics for GWAS of ALS and schizophrenia 
comprising over 100,000 unique individuals, we estimated the 
genetic correlation between ALS and schizophrenia to be 14.3% 
(95% CI 7.05-21.6; p = 1×10-4). Up to 0.12% of the variance in 
ALS was explained by schizophrenia polygenic risk scores (p 
= 8.4×10). We leveraged the apparent pleiotropic relationship 
between ALS and schizophrenia to identify five potential novel 
ALS-associated genomic loci at conditional false discovery rate 
< 0.01. Diagnostic misclassification in the schizophrenia cohort 
did not contribute significantly to our observations (BUHMBOX 
p = 0.94) and we estimated that 4.86% (2.47-7.13%) of ALS cases 
would need to be misdiagnosed as schizophrenia to observe our 
genetic correlation estimate under a true genetic correlation of 
0%. Our results indicate that the lifetime risk for comorbid ALS 
and schizophrenia increases from 1 in 40,000 to 1 in 34,336, 
which would require an incident cohort of 16,488 ALS patients to 
observe epidemiologically. Our findings suggest shared underlying 
biology between ALS and schizophrenia which will direct novel 
approaches in research and therapeutic development.
S08. Identifying clinically relevant imprinted gDMRs sensitive 
to a transient loss of DNA methylation in human differentiated 
cells
SJ Mackin1, K O’Neill2, R Irwin1, CP Walsh1.
1Genomic Medicine Research Group, Centre for Molecular 
Biosciences, Ulster University, Coleraine, BT52 1SA, UK. 2The 
Wellcome-Wolfson Institute for Experimental Medicine, Queen’s 
University Belfast, 97 Lisburn Road, Belfast, BT9 7AE, UK.
Background: Imprinted genes are autosomal, but only expressed 
from one parental allele and are often clustered in small groups. 
They play an important role in the regulation of normal mammalian 
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development. Differentially methylated regions (DMR) on 
each allele are important in regulating the genes, with marks 
being characterised as primary or secondary DMRs, depending 
on whether they are inherited from the germ cells or arise later, 
respectively. Imprinting disorders such as Prader-Willi Syndome 
(PWS) and Beckwith-Weidemann Syndrome (BWS) arise either 
from uniparental disomy or faulty DNA methylation. We wished 
to determine 1) which of the loci are most sensitive to loss of 
methylation 2) to more precisely define the sensitive regions and 
3) determine what happens at primary versus secondary imprints. 
Methods: Stable knockdowns of the maintenance methyltransferase 
DNMT1 were generated in hTERT-immortalised adult fibroblasts 
using shRNA. Genome wide methylation levels were assayed 
using the Illumina 450k BeadChip array and analysed using 
bioinformatic approaches. Results: We found that 1) the imprinted 
loci varied extensively in their sensitivity to loss of methylation 2) 
the extended locus involved in PWS was particularly sensitive 3) 
that loss of methylation at primary DMR appears to drive gains in 
methylation at secondary DMR. Conclusion: Our results point to a 
mechanistic link between primary and secondary DMR which may 
explain why imprints are difficult to reprogram in somatic tissues.
S09. Disease modelling with mesenchymal stromal cells and 
induced pluripotent cells uncovers the pathology of familial 
osteochondritis dissecans: from ACAN gene mutation to early 
onset osteoarthritis
M Xu1, EL Stattin2, G Shaw1, D Heinegård3, G Sullivan4, I Wilmut5, 
A Colman6, P Önnerfjord3, A Khabut3, A Aspberg3, P Dockery7, T 
Hardingham8, M Murphy1, F Barry1.
1Regenerative Medicine Institute (REMEDI), National University 
of Ireland Galway. 2Dept. of Medical Biosciences, Umeå 
University. 3Dept. of Clinical Sciences, Lund University. 4The 
Norwegian Center for Stem Cell Research, University of Oslo 
& Oslo University Hospital. 5Scottish Centre for Regenerative 
Medicine, University of Edinburgh. 6A*STAR Institute of Medical 
Biology, Singapore. 7Dept of Anatomy, National University of 
Ireland Galway, Ireland. 8Welcome Trust Centre for Cell-Matrix 
Research, University of Manchester.
Osteoarthritis (OA) is a degenerative joint disease that affects 
millions of people globally with no disease-modifying strategies 
yet available.  Our understanding of the pathology of OA is 
inadequate and this impedes investigation of efficient diagnosis 
and treatment. To expand our understanding of the underlying 
cellular pathology of OA, we studied a monogenic condition, 
familial osteochondritis dissecans (FOCD), associated with a 
known mutation in the ACAN gene. Patients with FOCD develop 
early onset OA with multiple joint involvement.
The objectives of the project were to investigate the cellular 
pathogenesis of FOCD by studying (a) chondrogenesis of patient-
derived bone marrow-mesenchymal stem cells (BM-MSCs) and 
(b) induced pluripotent stem cells (iPSCs) generated from patient 
fibroblasts.
Our findings revealed that the mutation resulted in a misfolded 
or unfolded aggrecan protein, which accumulated in the rough 
endoplasmic reticulum (rER) during protein production. The 
consistent accumulation resulted in ER stress throughout 
chondrogenesis. Moreover, the rER stress caused abnormal or 
disregulated global extracellular matrix (ECM) production and 
assembly. Importantly, ECM composition analysis indicated that 
the patient chondrocytes produced abundant amounts of OA-
associated markers.
Using patient-specific stem cell models, we have discovered a 
cellular pathogenesis of FOCD involving abnormal cell function 
and defective tissue formation, contributing to the OA phenotype.
S10. Genomic insights into the population structure and 
history of the Irish Travellers
E Gilbert1, S Carmi2, S Ennis3, J.F. Wilson4,5*, G.L. Cavalleri1*
1Molecular and Cellular Therapeutics, Royal College of Surgeons 
in Ireland, St Stephen’s Green, Dublin 2, Ireland. 2Braun School of 
Public Health, The Faculty of Medicine, The Hebrew University 
of Jerusalem, Jerusalem, Israel. 3School of Medicine and Medical 
Science, University College Dublin, Dublin, Ireland. 4Centre for 
Global Health Research, Usher Institute for Population Health 
Sciences and Informatics, University of Edinburgh, Teviot Place, 
Edinburgh, Scotland. 5MRC Human Genetics Unit, Institute of 
Genetics and Molecular Medicine, University of Edinburgh, 
Western General Hospital, Crewe Road, Edinburgh, Scotland,
Aims: The Irish Travellers are a nomadic population primarily 
found within Ireland and the UK. Consanguineous unions are 
common, and as a population they are socially and genetically 
isolated from the surrounding, “settled” Irish population. Previous 
low-resolution genetic analyses suggested a common Irish origin 
between the settled and the Traveller populations. It is not known, 
however, what is the extent of population structure within the Irish 
Traveller population, the time of divergence from the general Irish 
population, and the extent of autozygosity.
Methods: We recruited Irish Travellers from across Ireland and 
the UK. For inclusion, a participant had to have had at least three 
grandparents with a surname associated with the Irish Travellers. 
DNA was extracted from saliva samples, and genotypes were 
generated using the Illumina OmniExpress SNP genotyping 
platform. With this data, we investigated population structure 
using fineStructure, quantified the levels of autozygosity with 
PLINK, and estimated a time of divergence using a method based 
on Identity by Descent (IBD) segment sharing.
Results: We merged, cleaned, and analysed data from 42 Irish 
Travellers, 2232 settled Irish, 2039 British, 143 Roma Gypsies, 
and 931 individuals from 57 world-wide populations. We confirm 
an Irish origin for the Irish Travellers, demonstrate evidence for 
population substructure within the population, confirm high levels 
of autozygosity consistent with a consanguineous population, and 
for the first time provide estimates for a date of divergence between 
the Irish Travellers and settled Irish.
Conclusion: Our findings have implications for disease mapping 
within Ireland, and they additionally inform on the social history 
of the Irish Traveller population.
POSTER PRESENTATIONS:
P01. 16p13.11 duplications in a Northern Ireland Cohort
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S McNerlan1, V McConnell2.
1Northern Ireland Regional Genetics Laboratories, 2Northern 
Ireland Regional Genetics Service, Belfast City Hospital, Belfast 
Health & Social Care Trust.
Copy number variants at 16p13.11 have been described in 
association with a variety of neurodevelopmental disorders. While 
deletions of this region are perhaps better described, the clinical 
significance of the reciprocal duplication is less clearly defined. 
Phenotypes reported in association with the duplication include 
developmental delay, speech delay, behavioural difficulties and 
neurodevelopmental phenotype such as autism, schizophrenia 
and ADHD. However, the region appears to be subject to variable 
expressivity and incomplete penetrance.
To date we have detected duplications of 16p13.11 in 5 probands 
using oligonucleotide array CGH. Of these patients 3 showed 
duplications within the typical ~1.5Mb duplication region while 
2 patients had a larger ~2.8Mb duplication, encompassing all of 
the above region. The clinical phenotype of these patients will be 
described. Two of these patients have inherited the duplication 
from their mothers, one was a de novo finding and the inheritance 
of the others is currently unknown.  One of the maternal duplication 
carriers are also known to have a phenotype. 
Our data provides further clinical information on the phenotypic 
features of patients with this syndrome and provides more evidence 
for the pathogenic nature of this duplication.
P02. NI Regional Cancer Genetics Service Patient Satisfaction 
Questionnaire
J Scott, T O’Neill, D Jager
Northern Ireland Regional Genetics Service
Introduction – Patients referred to the NI Regional Cancer 
Genetics Service for genetic counselling were sent a questionnaire 
to evaluate patient satisfaction. The questionnaire focused on 
satisfaction surrounding the referral process, waiting times and 
communication during and after the appointment.
Method – One hundred patients, whose episode of care was 
completed between November 2015 and June 2016, were sent an 
anonymised structured questionnaire by post. Patients were seen 
by a genetic counsellor for assessment of their family history of 
cancer, predictive testing and genetic mutation screening
Results – To date (23/06/2016) the questionnaire response rate 
is 34%. So far 91% have expressed satisfaction with the service 
that they received. Useful comments and observations have been 
feedback in the questionnaire to aid service improvement. Data 
collection will be completed imminently to allow for complete 
analysis.
Discussion – Useful data has been collected which reinforces the 
service currently being delivered by genetic counsellors whilst 
also highlighting areas of service development.
P03. Detection of the 3 primary mitochondrial mutations in 
Leber’s hereditary optic neuropathy with a multiplex allele 
specific PCR / high resolution melt curve assay
S Eustace-Ryan1,F Ryan2, D Barton3, V O’Dwyer1, D Neylan2.
1National Optometry Centre, Dublin Institute of Technology, 
Kevin Street, Dublin 8. 2Biological Sciences, Dublin Institute of 
Technology, Kevin Street, Dublin 8. 3Centre For Medical Genetics, 
Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12.
Leber’s Hereditary Optic Neuropathy (LHON) is one of the most 
commonly inherited optic neuropathies and results in significant 
visual morbidity among young adults. 95% of LHON patients 
will present with one of three primary mitochondrial mutations; 
G3460A, G11778A and T14484C. We describe a novel real time 
diagnostic test to detect the three common mutations leading to 
LHON. The test uses a combination of multiplex allele specific 
PCR (ARMS PCR) in combination with high resolution melt 
curve analysis to detect the presence of the G3460A, G11778A 
and T14484C mutations.
PCR primer sets were designed to produce a control PCR product 
and PCR products only in the presence of the 3460A, 11778A and 
14484C mutations in a multiplex single tube format. Products 
produce discrete well separated melt curves allowing clear 
detection of the mutations. The test has proved to be robust, cost 
and time effective with the real time closed tube system taking 
approximately 1 hour to complete.
This test provides a simple, robust, easy to read output that is 
both cost and time effective, thus providing an alternative method 
to individual endpoint PCR – RFLP, PCR followed by Sanger / 
pyrosequencing and next generation sequencing. It will also allow 
diagnostic laboratories to detect 95% of LHON causing mutations 
in a single tube assay allowing diagnostic laboratories to avoid 
costly NGS assays for the vast majority of LHON patients, thus 
allowing resources to be focussed on patients with unknown 
mutations requiring further analysis.
P04. TACE levels in patients at very high risk of Major Adverse 
Cardiac Events
M Chemaly1, A Peace1,2, M Gibson2, M Clauss3,4, S Watterson1, T 
Bjourson1, V McGilligan1
1Northern Ireland Centre for Stratified Medicine, School of 
Biomedical Sciences, Ulster University, CTRIC building, 
Altnagelvin Hospital, L’Derry, BT47 6SB, 2Cardiology Department, 
Western Health and Social Care Trust, Glenshane Road, L’Derry, 
BT47 6SB, 3Department of Cellular and Integrative Physiology, 
Indiana University, West 10th Street, Indianapolis, Indiana 46202, 
4Centre for Molecular Bioscience, Ulster University, Cromore 
Road, Coleraine, BT52 1SA.
Atherosclerotic coronary artery disease (CAD) is a progressive 
chronic inflammatory condition that can lead to Major Adverse 
Cardiac Events (MACE) such as heart attacks. Currently there is 
no definitive test to predict MACE risk. Tumour necrosis factor 
alpha converting enzyme (TACE), also known as A Disintegrin 
And Metalloproteinase 17 (ADAM17) is a membrane-anchored 
protein responsible for the ectodomain shedding of a variety of 
transmembrane proteins such as cytokines, chemokines, growth 
factors and their receptors. TACE has been linked to several major 
acute and chronic inflammatory diseases including atherosclerosis. 
The aim of this study was to investigate if TACE may be a 
60 The Ulster Medical Journal
UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).
The Ulster Medical Society grants to all users on the basis of a Creative Commons Attribution-NonCommercial-ShareAlike 
4.0 International Licence the right to alter or build upon the work non-commercially, as long as the author is credited 
and the new creation is licensed under identical terms.
valuable predictive biomarker for CAD and MACE risk. TACE 
levels were measured in the plasma of CAD patients including 
those with acute coronary syndrome (ACS) and elective patients 
attending the catheterisation laboratory for coronary angiogram. 
TACE levels were measured using ELISA and quantitative real 
time PCR. Levels were compared with control samples collected 
from apparently healthy individuals and a subset of patients with 
no CAD as evidenced by coronary angiogram. Other factors that 
might affect TACE detection were also measured including sample 
type and storage time. To date 207 consecutive CAD patients and 40 
controls have been recruited to the study. Results demonstrate that 
CAD patients have higher levels of plasma TACE in comparison to 
controls. TACE protein levels were especially highest in those ACS 
and elective patients with a previous history of MACE. Results to 
date indicate that TACE may be a useful marker to predict disease 
progression and recurrent MACE in CAD patients.
P05. Investigating the role of a single nucleotide polymorphism 
in NRG1 in predisposition to breast and thyroid cancers 
UM McVeigh1, TP. McVeigh1,2, P Owens1, D Morris3, N Miller1, AJ 
Lowery1, MJ Kerin1
1Discipline of Surgery, Lambe Institute for Translational Research, 
National University of Ireland Galway  2Department of Clinical 
Genetics, Our Lady’s Children’s Hospital Crumlin  3Department of 
Biochemistry, National University of Ireland Galway.
Introduction: NRG1 (neuregulin1) is a candidate tumour 
suppressor gene. NRG1 encodes ligands for members of the 
ERBB family, and has been shown to be silenced by methylation 
in breast cancer1. Breast and thyroid cancers share some genetic 
loci (e.g. PTEN, STK11), and an increased risk of thyroid cancer 
has been noted in survivors of breast cancer2. A single nucleotide 
variant (C>G) in NRG1 (rs2439302), has been associated with 
increased risk of non-medullary thyroid cancer3. Aim: Our aim was 
to investigate the association between rs2439302 in NRG1 and 
predisposition to thyroid and breast cancers in an Irish population. 
Methods: A two-arm case-control study was undertaken. Patients 
with mutations in high-risk cancer susceptibility genes were 
excluded. Controls included adults with no personal or familial 
history of breast or thyroid cancers. Male controls were included 
in thyroid case- control analysis only. DNA was extracted from 
whole blood/buccal swabs by ethanol precipitation. Genotyping 
was performed using Taqman-based PCR.  Results: 257 patients 
with thyroid cancer, 518 with breast cancer and 367 unaffected 
controls were genotyped. Homozygous carriers of the variant 
were found to have an increased risk of thyroid cancer (OR1.89 
(1.21-2.95), p=0.005), but risk for mono-allelic carriers was 
not significantly increased (OR1.27 (0.87-1.84), p=0.21). The 
presence of the variant was not associated significantly with 
breast malignancy for mono-allelic (OR1.31 (0.95-1.8), p=0.095) 
or biallelic mutation carriers (OR1.15 (0.76-1.73), p=0.51).  
Conclusion: Homozygous carriers of the G allele were found 
to be at increased risk of thyroid cancer, but no association was 
observed between the variant and breast cancer. References:1Chua 
YL1, Ito Y, Pole JC et al, The NRG1 gene is frequently silenced 
by methylation in breast cancers and is a strong candidate for 
the 8p tumour suppressor gene. Oncogene. 2009;28(46):4041-
52.  2Nielsen SM, White MG, Hong S, et al, The Breast-
Thyroid Cancer Link: A Systematic Review and Meta-analysis. 
Cancer Epidemiol Biomarkers Prev. 2016;25(2):231-8. 
3Liyanarachchi S, Wojcicka A, Li W, et al, Cumulative risk 
impact of five genetic variants associated with papillary thyroid 
carcinoma. Thyroid. 2013;23(12):1532-40. 
P06. Expression and modulation of the family of UGT1A phase 
II metabolism genes by liganded Vitamin D receptor (VDR)
R Goodman, PD Thompson
Biomedical Science, Ulster University, Coleraine of Genetics
The UGT1A gene family encode (UGT) activity that facilitate 
the transfer of glucuronic acid to a range of xenogenous and 
endogenous substrates, the polar end products of which are better 
suited for elimination through urine and bile.  UGT1A genes 
exhibit an inducible pattern of expression regulated through the 
activities of such nuclear receptors (NRs) as pregnane X receptor 
(PXR) farensoid X receptor (FXR) and liver X receptor (LXR) 
that form a complex interactive network of ‘sensors’ to facilitate 
the elimination of potentially harmful metabolites and exogenous 
toxins.  We have previously reported that activation of vitamin D 
receptor (VDR) through both synthetic agonists and nutritionally 
derived ligands, can induce the expression of both phase I 
metabolic (CYP3A) and phase III transporter (ABCA1) genes. 
Little is known however, as to how activated VDR may impact 
upon the regulation of phase II genes such as UGT1A1.  In this 
study we demonstrate that ligand-activated VDR can significantly 
enhance the expression of several members of the UGT1A gene 
family.  With particular respect to UGT1A1, we identify within 
the proximal promoter region of this gene a functional vitamin D 
response element (VDRE) also recognized by PXR but distinct 
from previously established regulatory elements that mediate FXR 
and LXR signalling.  Based upon our data, we propose a model 
for VDR and circulating levels of vitamin D as maintaining stable 
expression of phase II and functionally related genes as a means 
to provide baseline protection against the effects of toxic xeno and 
endobiotic metabolites.
P07. Investigation of the oral microbiome for candidate 
markers of depression.
B Wingfield1, CR Lapsley2, A McDowell2, M McLafferty3, S 
Coleman1, MMcGinnity1, SM O’Neill3, Tony Bjourson2, EK 
Murray2.
1Intelligent Systems Research Institute, Ulster University; 
2Northern Ireland Centre for Stratified Medicine, Ulster University; 
3Psychology Research Institute, Ulster University. 
Depression is a complex disorder with multiple symptoms, 
including a persistent low mood, anhedonia and cognitive 
impairments, and is currently the third leading cause of global 
disability. The underlying pathophysiology of depression is poorly 
understood but a growing body of evidence supports an important 
role for the microbiome in the aetiology of depression and other 
psychiatric disorders. While much interest is currently focused 
on the role of the microbiome-gut-brain axis in brain physiology 
and neurochemistry, the importance of the oral microbiome has 
received little attention. The aim of this study is to characterise the 
oral microbiome in adults with severe depression versus matched 
controls with no history of the disease. To achieve this, participants 
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were asked to complete an online validated mental health survey 
and to provide a saliva sample.  We identified 46 individuals who 
met the DSM-V criteria for severe depression and 46 age and sex-
matched controls with no history of depression. Bacterial DNA 
was extracted from the saliva samples and 16S rRNA surveys were 
conducted using next generation sequencing. Differences in the 
bacterial community composition of the oral microbiota between 
patients and controls were determined.Metagenomic analyses 
were conducted using machine learning and computational 
intelligence algorithms using the 16S RNA data to generate 
inferred metagenome feature sets. Charting the oral microbiome 
in depressed patients could therefore provide new insights into 
the development of the condition, and lead to the identification of 
novel diagnostic and therapeutic response biomarkers.
P08. Expression and modulation of genes of pharmacokinetic 
relevance within enteric cells by liganded Vitamin D receptor 
(VDR)
EP Rodriguez1, D Doherty2, PD Thompson1
1School of Biomedical Science, Ulster University, Coleraine of 
Genetics, 2School of Dentistry, Medicine and Biomedical Science, 
Queens University Belfast 
The nuclear receptors (NRs) pregnane X receptor (PXR) and 
constitutive androstane receptor (CAR) modulate transcriptional 
networks that dictate the bioavailability of many endogenous and 
exogenous compounds such as steroid hormones and therapeutic 
drug compounds. Elucidating those factors that invoke PXR/
CAR activity has been important for understanding the genetic 
basis for both metabolic disease and inter-individual variations in 
drug response. PXR is most closely related to Vitamin D receptor 
(VDR) for which there is relatively little is known for how this NR 
may impact upon these same physiological processes.
In this study, we employed enteric cell models and ex-vivo based 
human colon explants to examine how activated VDR may impact 
upon the expression of genes of a metabolism and transporter 
function. We find that in relation to PXR and other evaluated 
NRs, VDR is the most efficient and dominant receptor for induced 
expression of CYP2B6, CYP3A4/5 and ABCA1. We note that upon 
activation with the synthetic agonist EB1089, VDR will achieve 
striking and sustained elevated expression of CYP3A4 at mRNA, 
protein and enzymatic level suggesting the potential for selective 
metabolic gene targeting through ligand design.  In addition, we 
report members of the UGT1A gene family to be novel VDR 
regulated genes, thus extending the known metabolic effects of 
vitamin D to also encompass expression of phase II (conjugating) 
genes. This study intimates that systemic vitamin D status and/or 
activating VDR ligands may have pharmacokinetic relevance to 
co-administered drug regimes.
P09. Analysis of Genetic Disease Markers in Ancient Irish 
Genomes
E O’Halloran1, J Conroy1, M Novak2, S Ennis1
ACoRD, School of Medicine and Medical Science, University 
College Dublin, Institute for Anthropological Research, Zagreb, 
Croatia.
Ancient genomes are often typically analysed with regard to 
ancestry and physical phenotype. Less common is examination 
and identification of genetic diseases, primarily due to the very 
low numbers of samples sequenced and poor level of sequencing 
related to the difficulties in sequencing from ancient DNA.
Here we present the results of analysing 21 ancient Irish genomes. 
The data were screened for a wide range of pathogenic genotypes 
and markers. Giving information for the potential effects and 
prevalence of certain conditions as well as the earliest known 
confirmation of their presence.
Using records of the remains, we also examined if any displayed 
phenotypes correlated to identified diseases.
P10. The NLRP3 Inflammasome and related receptors as 
biomarkers for Atherosclerotic MACE
C Mulholland1, L Gallagher,1, A Peace1,2, M Chemaly1, M Gibson2, 
T Bjourson1, V McGilligan1
1Northern Ireland Centre for Stratified Medicine, School of 
Biomedical Sciences, Ulster University, CTRIC building, 
Altnagelvin Hospital, L’Derry, BT47 6SB, 2Cardiology 
Department, Western Health and Social Care Trust, Glenshane 
Road, L’Derry, BT47 6SB
Coronary Artery Disease is the largest contributor of CVD, the 
leading cause of death worldwide.  It is caused by atherosclerosis, 
a build-up of cholesterol in the blood vessels and chronic 
inflammation. The NLRP3 inflammasome plays a critical role 
in the secretion of IL-1β, and there is significant evidence that 
it is involved in the pathogenesis of a number of inflammatory 
diseases including atherosclerosis. Recent studies demonstrate 
that particular cell surface receptors namely the scavenger receptor 
CD36 and the endocannabinoid receptor CB1 are involved in the 
activation and regulation of the NLRP3 inflammasome and they 
have also been implicated in the pathogenesis of atherosclerosis. 
The present study aimed to investigate expression and activation 
levels of the NLRP3 inflammasome, the CD36 and CB1 receptors 
in blood samples obtained from patients with atherosclerosis at 
very high risk of a Major Adverse Cardiac Event (MACE) such as 
a heart attack.  The cell signalling processes involved in NLRP3 
inflammasome activation were also investigated in a THP1 in 
vitro model of atherosclerosis. Results to date indicate increased 
expression of NLRP3 in patients at very high risk of MACE and 
also demonstrate that THP1 macrophages require both the CD36 
and CB1 receptors for optimal NLRP3 expression in response 
to oxidized LDL. These preliminary findings provide an insight 
into the mechanism of action of the NLRP3 inflammasome in 
atherosclerosis and prompt further exploration of this protein 
complex and its regulatory receptors as potential targets for 
prognostic and or therapeutic development in the strive towards a 
more personalised approach to the management of coronary artery 
disease.
P11. An exploration of de-novo mutations underpinning 
chronic refractory epilepsy
M McCormack1, S Heavin1, CP Doherty2, X Zhu3, E Heinzen3, DB 
Goldstein3, D Costello4, N Delanty1, GL Cavalleri1.
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1 Molecular and Cellular Therapeutics, Royal College of Surgeons 
in Ireland, Dublin, Ireland. 2 Department of Neurology, St James 
Hospital, Dublin, Ireland, 3 Institute for Genomic Medicine, 
Columbia University, New York, USA, 4 Department of 
Neurology, Cork University Hospital, Ireland
Approximately 30% of patients with epilepsy are refractory 
to anti-epileptic drug (AED) treatment and continue to have 
debilitating seizures that severely impact upon their quality of life. 
Exome sequencing in encephs etc has illustrated the importance 
of de-novo variants in the pathogenesis of rare neurological 
disorders. However, the contribution of de-novo mutations to 
pharmacoresistance in adult epilepsy is uncertain. In this study 
we investigated whether a trio whole exome sequencing paradigm 
could be applied to identify genetic causes of chronic, refractory 
epilepsy.
We selected adult patients (n=5) with onset of seizures after 5 
years of age, had failed ≥6 AEDs and were still experiencing >4 
disabling seizures per month. Patients were excluded if they had 
a potentially ‘explanatory’ lesion on MRI. Parents were exome 
sequenced to identify de-novo mutations and these were assessed 
bioinformatically for pathogenicity.
We confirmed the presence of coding de-novo mutations that were 
bioinformatically predicted to be functional and damaging in 3/5 
patients. One of these occurred in the gene DNM1L, which was 
recently implicated in pharmacoresistant epilepsy (Vanstone et al. 
EJHG, 2015;Nov 25). This represents a potential diagnostic yield 
of 20% however more data is required and more trios are currently 
being sequenced.
We have demonstrated the potential diagnostic yield of whole 
exome sequencing in a small number of adult patients with chronic 
refractory epilepsy. Identifying genetic mutations underpinning 
this disorder may provide new insight into the underlying biology 
and offers the potential for therapeutic intervention in the form of 
precision medicine.
P12. Whole Exome Sequencing to Identify Candidate 
Mutations for Familial IgA Nephropathy
CP Stapleton1, DM Connaughton2, PJ. Conlon2 and GL Cavalleri1
Department of Molecular and Cellular Therapeutics, RCSI, 
Dublin.1 Beaumont Hospital Kidney Centre, Dublin.2
IgA nephropathy (IgAN) is the most common form of glomerular 
nephritis worldwide1. Difference in incidences between ethnicities 
and familial inheritance patterns indicate this is a genetic disorder. 
An IgAN locus on chromosome 6q22-23 was identified via linkage 
analysis; however the causal gene remains elusive2. We set out to 
identify mutations underlying familial IgAN using whole exome 
sequencing.
DNA was collected on 25 (unaffected and affected) individuals 
across 6 families with IgAN. Families were chosen on the basis 
of having at least 2 affected members with IgAN. We carried 
out full exome sequencing on 12 of the affected members from 
these families. Depending on the pattern of inheritance in a given 
family, mutations that fitted a dominant, recessive or compound 
heterozygote model of inheritance were screened for. These 
variants were then filtered based on being shared between affected 
individuals within a family, their minor allele frequency, region, 
function and predicted deleterious nature.
We identified a number of potential candidate mutations in these 
families and including a mutation in the gene COL4A5 which was 
previously described as pathogenic3. Mutations in COL4A5 have 
previously been found in individuals with Alport syndrome, a 
disease which is often mistaken for IgAN. We are currently working 
to confirm these candidate mutations via Sanger sequencing and 
will be screening for segregation.
References: 1Bisceglia et al. Am J Hum Genet 2006;79(6):1130-4. 
2Gharavi et al., Nat Genet 2000;26:354-7. 3Zhou et al. Am J Hum 
Genet 1992;50(6): 1291-1300.
P13. A computational approach to increase understanding of 
atherosclerosis
A Parton1, V McGilligan1, M O’Kane2, S Watterson1*
1Northern Ireland Centre for Stratified Medicine, Ulster University, 
C-TRIC, Altnagelvin Hospital Campus, Derry, Co Londonderry, 
Northern Ireland, BT47 6SB. 2Department of Clinical Chemistry, 
Altnagelvin Hospital, Western Health and Social Care Trust, 
Londonderry, Northern Ireland, BT47 6SB.
Atherosclerosis is a chronic inflammatory disorder that is 
responsible for approximately 71% of incidents of cardiovascular 
disease. A mathematical model of atherosclerosis has been 
developed, capturing the cell types and proteins involved in 
atheroma formation and describing the dynamics of disease 
progression. This is the first model of this type to be developed 
using open systems biology standards. We have predicted tertiary 
protein structures for all the proteins involved in this atherosclerosis 
model and all of their recorded mutations, using phase 3 sequence 
data obtained from the 1000 Genomes Project. By comparing 
the electrostatic potentials of these tertiary structures, we predict 
how the dynamics of atherosclerosis stratifies across population 
subgroups.
P14. A feasibility study investigating whether methylation 
of the oxytocin receptor (OXTR) can serve as a potential 
biomarker for response to oxytocin administration in women 
during and after labour.
J Elwood1, O Sunnotel3, DJ Stockdale1, EK Murray3 AJ Bjourson, 
AF Bell2, M Sinclair1
1Institute of Health and Nursing Research, Ulster University, 
2College of Nursing, University of Illinois at Chicago, 3Northern 
Ireland Centre for Stratified Medicine, Ulster University.
The aim of this pilot study was to test the feasibility of carrying 
out a large scale study using this design to investigate whether 
methylation of the oxytocin receptor (OXTR) can serve as a 
potential biomarker for response to oxytocin administration in 
women during and after labour.
Background: Oxytocin is a nine-amino acid peptide with hormonal 
and neurotransmitter functions during labour and lactation. We 
hypothesised that a difference in methylation levels of the oxytocin 
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receptor (OXTR) gene may impact the woman’s ability to become 
established in labour and her response to oxytocin administration.
Method: Blood samples were taken pre-birth and postnatally 
from 21 women and subjected to DNA methylation analysis of 
the OXTR gene by pyrosequencing. Methylation status of CpG 
sites -924 and -934 upstream from the initiation transcription 
site (ITS) of the OXTR gene was determined. Expression of the 
OXTR gene before and after birth was measured using qPCR. 
Global methylation levels were examined using Luminometric 
Methylation Assay (LUMA).
Results: We found both hypo and hypermethylation of OXTR 
promoter at CpG sites -924 and -934 in individual samples, however 
we observed no profound changes in overall OXTR methylation 
levels within the patient cohort at these CpG sites. We found a 
strong correlation between OXTR promoter methylation levels 
found in whole blood and those found in matched PMBC samples. 
Global methylation analysis using Luminometric Methylation 
Assay (LUMA) revealed no significant differences between whole 
blood and PMBC.
Conclusions: A larger sample is required to determine whether 
OXTR methylation status is predictive of response to oxytocin 
administration. Whole blood sampling is a suitable alternative 
for OXTR methylation analysis in a larger cohort of women 
undergoing labour.
P15. Investigating microRNAs as Serum Markers of Elevated 
Blood Pressure
SM Lynch1, M Ward2, H McNulty2, G Horigan2,  JJ Strain2, J 
Purvis3, M Tackett4, DJ McKenna1
1Genomic Medicine Research Group, Biomedical Sciences 
Research Institute, Ulster University, Cromore Road, Coleraine, 
N. Ireland, BT52 1SA, 2Northern Ireland Centre for Food and 
Health (NICHE), Biomedical Sciences Research Institute, Ulster 
University, Cromore Road, Coleraine, N. Ireland, BT52 1SA, 
3Department of Cardiology, Altnagelvin Area Hospital, Western 
Health and Social Care Trust, Derry, N Ireland, 4Firefly BioWorks, 
an Abcam Company, Sample Processing, One Kendall Square, 
Building 1400W 3rd Floor, Cambridge, MA 02139, USA
Background: Cardiovascular disease (CVD) is the leading cause 
globally of morbidity and mortality. microRNAs (miRNAs) are 
small, non-coding RNAs which have a fundamental role in the 
pathology of various diseases including CVD. Circulating serum 
levels of miRNAs have been proposed as potentially valuable 
markers of heart failure, stroke, myocardial infarction and arterial 
hypertension, but the specific miRNAs involved and their function 
remains unclear. Therefore, this pilot study aims to profile miRNA 
expression in premature CVD patients to identify which miRNAs 
correlate best with hypertension.
Methods: The Multiplex Circulating miRNA Assay with FireflyTM 
Particle Technologies was used to profile 68 miRNAs on a 
cardiology focus panel in serum samples from 170 premature CVD 
patients recruited from Altnagelvin Area Hospital and screened for 
the C677T polymorphism in methylenetetrahydrofolate reductase, 
a risk factor for hypertension.  Samples were collected at baseline 
and following intervention with riboflavin, a co-factor for MTHFR, 
which significantly lowers blood pressure specifically in adults 
with this polymorphism. Statistical analysis was used to correlate 
miRNA expression with blood pressure, MTHFR genotype and 
other relevant clinical data.
Results: The assay successfully measured miRNA expression in 
the sample set. miRNAs which expressed differentially between 
MTHFR genotype groups were highlighted and the functional 
significance of these miRNAs was assessed using bioinformatics 
to identify target genes involved in CVD.
Conclusions: The data provides further evidence that using 
specific miRNAs as serum markers could aid early prediction of 
CVD and may lead to better diagnostic modalities and therapeutic 
regimes.
P16. Investigating the association between genetic and 
epigenetic variability in the 5-HTT and BDNF genes and 
depression in young adults.
CR Lapsley1, S Baldemor1, M McLafferty2, SM O’Neill2, AJ 
Bjourson1, EK Murray1
1Northern Ireland Centre for Stratified Medicine, Ulster University; 
2Psychology Research Institute, Ulster University. 
Gene-environment interactions, particularly in genes related 
to regulation of serotonin and neuronal function, have been 
implicated in the aetiology of depression. Allelic variations in the 
5’ flanking transcriptional region of the serotonin transporter gene 
(5-HTTLPR) and higher levels of promoter DNA methylation 
are associated with depression. Brain derived neurotrophic factor 
(BDNF) plays an important role in neuronal differentiation and 
survival, and is also involved in regulation of serotonin. A single 
nucleotide polymorphism in the BDNF gene, leading to a valine 
to methionine substitution at codon 66 (Val66Met), and increased 
methylation of the BDNF promoter have also been associated with 
depression. The goal of this study is to determine whether length 
of the 5-HTTLPR, prevalence of the Val66Met polymorphism of 
the BDNF gene and DNA methylation in both 5-HTT and BDNF 
promoter regions are associated with depression in the student 
population. First year students provided a saliva sample for genetic 
analysis and completed an online mental health survey. Presence 
and severity of depression was determined from survey responses 
based on DSM-IV criteria. Length of the 5-HTTLPR was 
determined by PCR and gel electrophoresis and presence of the SNP 
at BDNF rs6265 and examined using restriction fragment length 
polymorphism analysis. Bisulphite-treated DNA was amplified by 
PCR and pyrosequencing assays used to determine methylation 
patterns of BDNF and SERT. Our preliminary findings suggest that 
genetic and epigenetic variation in the 5HTT and BDNF genes are 
associated with depression in the student population and may be 
candidate biological markers to assist in diagnosis.
P17. The potential role of Propionibacterium acnes in prostate 
oncogenesis
E Yankova1, E Barnard2, D McCafferty3, L Martin3, D Fairley4, D 
O’Rourke5, M Catherwood6, S Patrick2, A McDowell 1,2
1Centre for Stratified Medicine, Ulster University. 2Centre for 
Infection and Immunity, Queen’s University Belfast. 3School 
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of Pharmacy, Queen’s University Belfast. 4Department of 
Microbiology, Royal Victoria Hospital. 5Histopathology 
Laboratory, Belfast City Hospital, Belfast Health and Social Care 
Trust. 6Department of Haematology, Belfast City Hospital, Belfast 
Health and Social Care Trust
BACKGROUND: Prostate cancer is the most common male 
cancer in the UK, where it kills approximately 11,000 men 
annually. There has been growing interest in the role played by 
the anaerobic bacterium Propionibacterium acnes, an important 
component if the skin microflora, in the aetiology of the condition 
via a chronic, asymptomatic infection of the prostate leading to 
oncogenesis.
METHODS: A quantitative real-time PCR (qRT-PRC) assay 
for retrospective detection of P. acnes in formalin-fixed paraffin 
embedded sections from archived prostate samples was developed. 
An in vitro infection model of prostate infection with P. acnes is 
being optimised, which should allow us to get insight into the 
dysregulation P. acnes infection causes in prostate epithelial cells.
RESULTS: A total of 81 biopsy samples, representing one or 
both prostate lobes, were examined from 53 patients with prostate 
carcinoma, versus 111 samples from 60 patients whose biopsies 
were histologically normal, and the assay revealed that 35% 
of cancerous prostate samples were positive for the presence of 
P. acnes, compared with only 8% of the disease-free samples 
(p<0.001). Transcriptomic studies of chronically infected epithelial 
cells revealed a significant dysregulation of genes, previously 
associated with prostate cancer development, progression and 
metastasis.
CONCLUSIONS: Our study reveals that P. acnes is significantly 
associated with cancerous prostate tissue and has a capacity 
to initiate a host response in vitro, suggesting it may stimulate 
oncogenesis as a result of a chronic infection. Investigation is 
needed of the association of different phylogenetic types of P. 
acnes and their ability to initiate molecular dysregulation resulting 
in oncogenesis in vitro.
P18. Whole exome and total RNA sequencing reveals candidate 
drivers in the development of oral squamous cell carcinoma.
C Conway1,2, LS Stead2, HM Wood2 and PH Rabbitts2.
1Northern Ireland Centre for Stratified Medicine, Biomedical 
Sciences Research Institute, Ulster University, 2Leeds Institute of 
Cancer and Pathology, University of Leeds.
Oral squamous cell carcinoma (OSCC) is one of the top ten most 
prevalent cancers in the world. Prognosis is poor and quality of life 
is commonly reduced for patients who survive. OSCC is thought 
to progress via a premalignant stage called dysplasia. Effective 
treatment of dysplasia prior to malignant transformation, or the 
ability to more accurately predict the 10-20% of dysplasias that 
will progress to OSCC, is an unmet clinical need.
With the aim to better understand the biology of OSCC 
development, and attempt to identify potential markers of early 
disease and therapeutic targets, we performed parallel whole 
exome sequencing and total RNA sequencing on 16 micro-
dissected formalin-fixed paraffin embedded dysplasia and their 
associated OSCC. These are the largest omic analyses on matched 
patient samples from the oral cavity in non-HPV infected patients 
where all dysplasias are associated with progression to OSCC, that 
has been performed to date.
Whole exome analysis revealed that every OSCC and adjacent 
associated dysplasia sample did have a common clonal ancestor, 
with many shared potential drivers of progression, but that there is 
also considerable genomic heterogeneity between associated pre-
invasive and invasive disease, as seen in a previous study1. RNAseq 
analysis revealed differences in the immune cell signatures 
present at different disease stages, distinguished early events 
in pathogenesis from later events and identified several novel 
coding and non-coding candidates with potential involvement 
in oral dysplasia development and malignant transformation. 
These findings merit further investigation in a larger retrospective 
longitudinal study of patients with oral dysplasia.
1Wood HM, Conway C, Daly C, et al. The clonal relationships 
between pre-cancer and cancer revealed by ultra-deep sequencing. 
J Pathol 2015; 237:296-306.
P19. Evaluation of Potential Mitochondrial Therapies using a 
Novel Complex I Assay
DM Maloney1, N Chadderton1, S Millington-Ward1 and GJ Farrar1
1Smurfit Institute of Genetics, School of Genetics & Microbiology, 
Trinity College Dublin, Dublin 2, Ireland
Many disorders involving tissues, which have significant energy 
requirements, involve mitochondrial dysfunction often due 
to mutations affecting the mitochondrial genome. Some such 
mutations can involve genes coding for subunits of complex I of 
the electron transport chain leading to a complex I deficiency in 
disorders such as Leber Hereditary Optic Neuropathy (LHON) 
amongst others. Mitochondrial dysfunction leads to a lack of 
energy production and ultimately the death of the cell. In disorders 
such as LHON, retinal ganglion cells (RGCs) are affected, leading 
to retinal dysfunction. These observations have prompted interest 
in exploring innovative therapeutics to modulate mitochondrial 
disorders involving complex I deficiency. The Farrar laboratory 
has explored candidate gene therapies for complex I deficiency 
using Ndi1, a yeast gene which is a complex I homologue.
In order to test the efficacy of candidate therapies, we have 
developed a robust, empirical assay of mitochondrial function. 
Previous assays measured the level of NADH oxidation in a 
sample, both before and after rotenone as a measure of complex I 
activity. To optimally distinguish between the activity of complex 
I and the potential therapeutic, the assay was modified with the 
addition of a second inhibitor which allowed specific measurement 
of the therapeutic, such as Ndi1. Given that this is an in vitro 
assay, it enables large-scale screening of potential therapeutics and 
ensures only those that show strong evidence of efficacy are then 
tested in vivo. In combination with other quantitative assays such 
as Reactive Oxygen Species (ROS) generation this allows detailed 
evaluation of the health of mitochondria within a sample.
P20. A Study of Genes that Function in the Centrosome for 
Involvement in the Aetiology of Schizophrenia and Associated 
Cognitive Deficits.
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M Flynn1, L Whitton1, D Cosgrove1, C Morrison2, J Walters3, D 
Rujescu4, A Corvin5, G Donohoe1, D Morris1
1Cognitive Genetics and Cognitive Therapy Group, Neuroimaging 
and Cognitive Genomics (NICOG) Centre & NCBES Galway 
Neuroscience Centre, School of Psychology and Discipline of 
Biochemistry, National University of Ireland Galway, Ireland. 
2Centre for Chromosome Biology, Discipline of Biochemistry, 
National University of Ireland Galway, Ireland,  3MRC Centre 
for Neuropsychiatric Genetics and Genomics, Cardiff University, 
UK,  4Department of Psychiatry, University of Halle, Halle, 
Germany, 5Neuropsychiatric Genetics Research Group, Institute of 
Molecular Medicine and Discipline of Psychiatry, Trinity College 
Dublin, Ireland.
Schizophrenia is an adult-onset mental illness with that impacts 
cognitive function. The largest GWAS has revealed 108 loci 
associated with schizophrenia risk but how variation affects genes 
and impacts brain function to increase risk is largely unknown.
The centrosome is the microtubule organising centre of the cell 
and seeds the growth of the primary cilium. The disproportionate 
number of brain disorders associated with centrosomal genes 
suggests the organelle underlies normal brain and cognitive 
development.  Schizophrenia is neurodevelopmental and cognitive 
deficits are a core element of the disorder. We hypothesise that 
some of the newly identified risk genes for schizophrenia will 
function in the centrosome and variants in these genes will be 
associated with cognitive deficits.
Cross-referencing genes with centrosomal functions with genes 
from schizophrenia GWAS, identified six candidate genes; 
SDCCAG8, MAD1L1, GIGYF2, MPHOSPH9, PRKD1 and 
MAPK3. The effect of risk SNPs on cognition was examined 
using an Irish dataset of psychosis cases and controls (n=1,236) 
using linear regression. Among the associations identified, the 
SDCCAG8 risk SNP was shown to affect attribution style, a 
measure of social cognition (P=0.001). The MAD1L1 risk SNP 
was associated with poorer performance on episodic memory tasks 
(P=0.003).
A suitable replication dataset was not available for social cognition 
measures. We attempted replication for episodic memory results in 
UK and German samples but results were non-significant. Overall, 
we have identified a number of schizophrenia risk genes that 
function in the centrosome but further larger datasets are required 
to establish a role for these genes in cognition.
P21. Analysis of Candidate Schizophrenia Risk Gene CHD7 
and Associated Interacting Genes Suggests a Role in Cognition 
for Novel Network of Genes.
L Whitton1, D Cosgrove 1, C Clarkson2, D Harold3,4, K Kendall5, 
A Richards5, K Mantripragada5, MJ Owen5, MC. O’Donovan5, J 
Walters5, A Hartmann6, B Konte6, D Rujescu6, WTCCC2, M Gill3, 
A Corvin3, S Rea2, G Donohoe 1, DW Morris1
1Cognitive Genetics and Cognitive Therapy Group, Neuroimaging, 
Cognition & Genomics (NICOG) Centre & NCBES Galway 
Neuroscience Centre, School of Psychology and Discipline of 
Biochemistry, National University of Ireland Galway, Ireland. 
2Centre for Chromosome Biology, Discipline of Biochemistry, 
National University of Ireland Galway, Ireland. 3Neuropsychiatric 
Genetics Research Group, Institute of Molecular Medicine and 
Discipline of Psychiatry, Trinity College Dublin, Ireland. 4School 
of Biotechnology, Dublin City University, Dublin, Ireland. 5MRC 
Centre for Neuropsychiatric Genetics and Genomics, Cardiff 
University School of Medicine, Cardiff, UK. 6Department of 
Psychiatry, University of Halle, Halle, Germany1
Epigenetic mechanisms are an important heritable and dynamic 
means of regulating various genomic functions, including gene 
expression to orchestrate brain development. These processes 
when perturbed are thought to contribute to schizophrenia (SZ). A 
core feature of SZ is cognitive dysfunction. GWAS have identified 
108 genomic loci associated with SZ risk, containing 350 genes. 
My aim was to identify genes that have epigenetic functions which 
map to loci associated with SZ, and to test the associated SNPs for 
association with cognitive deficits. Risk SNPs in 8 genes: BCL11B, 
CHD7, EP300, EPC2, GATAD2A, KDM3B, RERE and SATB2 
were analysed using an Irish dataset of psychosis cases and controls 
(n=1235) who had completed tests across 5 cognitive domains. Five 
of the eight variants had significant associations with at least one 
cognitive task. Strongest associations were for CHD7 (rs6984242) 
for IQ (p=0.001) and episodic memory (p=0.007). These results 
did not replicate in independent samples. We link rs6984242 to 
CHD7 via a long range expression quantitative trait loci (eQTL) 
and CHD7 has not been previously reported as a candidate risk 
gene for SZ. To further explore its novel association with SZ, we 
identified a set of 45 interacting genes and used SNPs across these 
genes to develop a polygenic risk score for SZ, independent of 
CHD7 itself. This score was tested for association with cognitive 
function. Significant associations(p<0.05) were found with 3 
measures of IQ, 2 measures of episodic memory and 1 measure 
of working memory, suggesting a role for this gene network in 
cognition.
P22. Folate-sensitive differentially methylated regions: are we 
trying to predict the unpredictable?
A Harrison1, K Pentieva2, M Ozaki1, H McNulty2, A Parle-
McDermott1
1Nutritional Genomics Group, School of Biotechnology, Dublin 
City University, Dublin 9, 2Northern Ireland Centre for Food & 
Health, School of Biomedical Sciences, University of Ulster, 
Coleraine, Northern Ireland.
The relevance of nutrition and other environmental influences on 
epigenetic modifications including DNA methylation is a topic of 
considerable interest. Folate One Carbon Metabolism (FOCM) 
is the principal supplier of the methyl groups required for DNA 
methylation, giving folate status a strong biological plausibility 
of having an impact on an individual’s and an offspring’s DNA 
methylation profile at both the mitotic and meiotic level.
We sought to identify DNA methylation sites in the human genome 
that are sensitive to folate status i.e., Folate-sensitive Differentially 
Methylated Regions (FS-DMR) using a folic acid intervention trial 
in pregnant women known as FASSTT (Folic Acid Supplementation 
in the Second and Third Trimesters). To minimize the amount of 
DNA methylation ‘noise’ due to non-folate related factors such as 
other environmental stimuli and individual genetic variation, we 
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compared the DNA methylation profile of the same individual pre- 
and post- intervention to identify putative FS-DMR.  We selected 
six healthy pregnant women, three from the folic acid intervention 
arm and three from the placebo arm of the trial. We performed 
MeDIP (Methylated DNA Immunoprecipitation) on all 12 samples 
and hybridized to a Roche Nimblegen Delux 2.1M promoter array. 
While we observed DNA methylation changes pre- and post- folic 
acid intervention in each individual, the actual DNA methylation 
sites were not consistent across all three individuals. Of course, 
it is possible that a more in-depth Next Generation Sequencing 
approach might yield our elusive FS-DMRs.  However, the 
published literature to date does not appear to support such a 
promise.
P23. A Novel Approach to Promoter Identification – 
Development of a Ganglion Cell-specific Promoter for AAV-
mediated Gene Therapy
KS Hanlon1, S Millington-Ward1, N Chadderton1, A Palfi1, P 
Humphries1, PF Kenna1,2,  GJ Farrar1
1Ocular Genetics Unit, Smurfit Institute of Genetics, Trinity 
College Dublin, Dublin 2, Ireland, 2Royal Victoria Eye and Ear 
Hospital, Adelaide Road, Dublin 2, Ireland
The loss of retinal ganglion cells (RGCs) is a hallmark of a 
number of retinopathies. There are a number of gene therapies 
being developed that have shown efficacy in preserving RGCs 
when administered using an AAV vector. Localising expression of 
any therapeutic to the target cell type (ganglion cell layer, GCL) 
would represent a significant optimisation of the approach. The 
packaging capacity of AAV (4.7kb) imposes a limit on the size 
of promoters and genes relevant for AAV-mediated gene delivery. 
Few GCL-specific promoter sequences have been defined of a size 
suitable for use in AAV-guided gene expression.
Exploring this, a panel of genes was chosen with GCL-limited 
expression profiles. A pipeline program was developed that analysed 
regions upstream of these genes for sequence conservation across 
placental mammals (as a proxy for putative promoter function), 
weighted by enriched GCL expression levels. Adopting this 
strategy, ganglion cell promoter 1 (GCP1), demonstrating the key 
features outlined above, was identified. To test its function, GCP1 
(2.2kb in size) was engineered into an AAV2 virus expressing 
EGFP.
Here we demonstrate the effectiveness of GCP1 in localising EGFP 
expression to the GCL when administered via intravitreal injection. 
Furthermore, absence of EGFP expression was demonstrated when 
targeted towards photoreceptors via subretinal injection, verifying 
GCP1 tissue-specificity. Expression of AAV2.GCP1-EGFP was 
compared to expression from a non-specific promoter construct, 
AAV2.CMV-EGFP. GCP1-EGFP was shown to provide equivalent 
expression to CMV-EGFP in the GCL. GCP1 thus offers a tissue-
specific promoter option, suitable for deployment within AAV 
vectors without compromising functionality.
P24. Targeting hypoxic prostate tumours using the novel 
hypoxia-activated prodrug OCT1002 inhibits expression of 
genes associated with malignant progression.
H Nesbitt1, NM Byrne1, 5, L Ming1, J Worthington1, 2, RJ Errington3, 
LH Patterson4, PJ Smith4, SR McKeown1,4, DJ McKenna1 
1Biomedical Sciences Research Institute, University of Ulster, 
Cromore Road, Coleraine, Northern Ireland, BT52 1SA, UK. 
2Axis Bioservices Ltd, Coleraine, Northern Ireland, BT51 3RP, 
UK, 3BioStatus Ltd, Shepshed, Leicestershire LE12 9NP, UK, 
4OncoTherics Ltd, Shepshed, Leicestershire LE12 9NP, UK, 
5Garvan Institute of Medical Research, 384 Victoria Street, Sydney, 
New South Wales 2010, Australia.
Purpose: Hypoxia is a common hallmark of the tumour 
microenvironment. Recently we have shown the anti-androgen 
bicalutamide induces profound hypoxia in prostate tumours in 
vivo. This resulted in the promotion of epithelial to mesenchymal 
transition.  Here we target tumour hypoxia using a novel 
unidirectional hypoxia-activated prodrug OCT1002 to enhance the 
anti-tumour effect of bicalutamide. 
Experimental Design: The effect of OCT1002 treatment on 
LNCaP-luc cells was measured in normoxia and hypoxia in vitro. 
In vivo, tumour growth and lung metastases were measured in mice 
treated with bicalutamide, OCT1002 or a combination. Dorsal skin 
fold chambers were used to image tumour vasculature in vivo. 
Longitudinal genetic changes in tumours were analysed using 
PCR.
Results: Reduction of OCT1002 to its active form (OCT1001) 
decreased LNCaP-luc cell viability. In LNCaP-luc spheroids, 
OCT1002 caused increased apoptosis and decreased clonogenicity. 
In vivo, treatment with OCT1002 alone or with bicalutamide, 
showed significantly greater tumour growth control and reduced 
lung metastases compared to controls. Re-establishment of the 
tumour vasculature following bicalutamide-induced vascular 
collapse is inhibited by OCT1002. Significantly, the up-regulation 
of RUNX2 and its targets caused by bicalutamide alone were also 
blocked by OCT1002. 
Conclusions: OCT1002 selectively targets hypoxic tumour 
cells and enhances the anti-tumour efficacy of bicalutamide. 
Furthermore, bicalutamide causes changing genetic profiles during 
treatment, with development of a more malignant genotype; 
OCT1002 can block this effect. This study indicates that more 
attention should be attached to understanding genetic changes 
that may occur during treatment. Early targeting of hypoxic cells 
with OCT1002 can provide a means of inhibiting prostate tumour 
growth and malignant progression. 
P25. Regulation of miR-200c and miR-141 by methylation in 
prostate cancer
SM Lynch 1, KM O’Neill 1,2, MM McKenna 3, CP Walsh 1, DJ 
McKenna1
1Biomedical Sciences Research Institute, University of Ulster, 
Cromore Road, Coleraine, BT52 1SA, UK. 2School of Medicine, 
Dentistry and Biomedical Sciences, Queen’s University Belfast, 
97 Lisburn Road, Belfast, BT9 7BL, UK, 3Department of Cellular 
Pathology, Western Health & Social Care Trust, Altnagelvin Area 
Hospital, Glenshane Road, Co. Derry, BT47 6SB, UK.
Background: In prostate cancer (PCa), abnormal expression 
of several microRNAs (miRNAs) has been previously reported. 
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Increasing evidence shows that aberrant epigenetic regulation is 
a contributing factor to their altered expression in cancer. In this 
study we investigate whether expression of miR-200c and miR-141 
in PCa is related to the DNA methylation status of their promoter.
Methods: PCR analysis of miR-200c and miR-141, and CpG 
methylation analysis of their common promoter, was performed 
in PCa cell-lines and in FFPE prostate biopsy specimens. The 
functionality of miR-200c and miR-141 expression in prostate 
cancer cells was assessed by a series of in vitro bioassays.
Results: miR-200c and miR-141 expression correlates inversely 
with the methylation status of the miR-200c/miR-141 promoter 
in PCa cells. In PC3 cells, miR-200c and miR-141 expression is 
elevated by treatment with the demethylating agents suggesting 
their expression is linked to methylation. Expression of miR-200c 
and miR-141 in prostate biopsy tissue was inversely correlated with 
methylation in CpG sites closest to the miR-200c/miR-141 loci. 
Over-expression of miR-200c in PC3 cells inhibited growth and 
clonogenic potential, as well as inducing apoptosis.  Expression 
of the genes DNMT3A and TET1/TET3 were down-regulated by 
miR-200c and miR-141 respectively. Finally, treatment with the 
soy isoflavone genistein caused demethylation of the promoter 
CpG sites closest to the miR-200c/miR-141 loci resulting in 
increased miR-200c expression.
Conclusions: Our findings provide evidence that miR-200c and 
miR-141 are under epigenetic regulation in PCa cells. Profiling 
their expression and methylation status may have potential in the 
improved diagnosis and prognosis of PCa.
P26. Folic acid supplementation in late gestation and the effects 
on DNA methylation in the offspring
RE Irwin1, A Caffrey2, K Pentieva2, H McNulty2. CP. Walsh1
1Dept. of Genomic Medicine, Ulster University, Coleraine, 
2Northern Ireland Centre for Food and Health, Ulster University, 
Coleraine.
Increasingly accurate surveys of human health throughout the life 
course has led experts to propose that stresses on the child while 
still in the mother’s womb can affect the individual’s health much 
later in life. Such long-term effects on health are thought to be 
mediated by a semi-permanent trace on the genes of the affected 
person called an epigenetic mark. Epigenetic mechanisms, such 
as DNA methylation, are dynamic during pregnancy whereby 
epigenetic marks are seeded which persist throughout the lifetime 
of the developing child. It has been suggested that these patterns 
may be altered by the mother’s diet, particularly folate – a key 
component in the DNA methylation cycle. Currently, mothers are 
universally recommended to supplement their diet with 400µg 
folic acid/day as a preventative measure against neural tube defects 
in the offspring prior to and during the first trimester. However, 
there remains no clinical recommendation as to whether mothers 
should continue supplementation during the final two trimesters 
and the potentially heritable effects on DNA methylation. 
Observational studies have suggested that folate-rich maternal 
diets are associated with changes in DNA methylation of the child 
during this period of gestation. We present here the results of a 
randomised control trial (FASSTT study) examining the effects of 
folic acid supplementation in late gestation (week 12 onwards) on 
DNA methylation of several gene classes in offspring cord blood 
samples. We report small but significant sex-specific differences 
between the two intervention groups. These preliminary results 
indicate that folic acid supplementation throughout pregnancy may 
exert significant effects on cord blood DNA methylation.
P27. Whole exome sequencing for the identification of variants 
associated with new-onset diabetes after transplantation
KA Benson1, AP Maxwell1,2, AJ McKnight1
1Nephrology Research Group, Centre for Public Health, Queen’s 
University Belfast,  2Regional Nephrology Unit, Belfast City 
Hospital
Introduction: New-onset diabetes after transplantation (NODAT) 
is a common complication of kidney transplantation which increases 
risk of subsequent graft failure, cardiovascular complications 
and death. NODAT is defined as the new requirement for oral 
hypoglycaemic agents or insulin as a result of hyperglycaemia after 
renal transplant. The first genome wide association study (GWAS) 
for NODAT was published by our group in 2014; seven of the eight 
top-ranked, common SNPs are implicated in β-cell apoptosis.
Methods: To further understand the genetic architecture of the 
NODAT phenotype we used whole exome sequencing for 134renal 
transplant recipients from a Northern Ireland renal transplant 
cohort. We sequenced 53 individuals with NODAT (cases)and 
81 transplant recipients without NODAT (controls). Library 
preparation was performed using the Ion TargetSeq™ Exome 
Kit with samples sequenced on an Ion Torrent Proton sequencer. 
TheIon OneTouch 2 for emulsion PCR and Ion Enrichment System 
were used. Association analysis was performed using PLINK 
Version 1.9 to identify variants associated with NODAT (with age 
and weight at transplant included in the regression model). 
Results: Following appropriate quality control, initial analysis 
identified 6 variants nominally associated with NODAT 
(Ptrend<1x10-5)using the test for trend. The top two hitsrs2305765 
(Ptrend=2.50x10-6; PLR=1.0x10-4 OR:0.07(95% CI:0.02-0.26))
andrs8110964 (Ptrend=4.47x10-6; PLR=1.4x10-4 OR:0.04 (95% 
CI:0.01-0.20))were in linkage disequilibrium (r2=0.86) in the 
MYO9B gene. Variants in this gene have previously been associated 
with autoimmune diseases including type 1 diabetes. We propose 
MYO9B as a candidate gene for NODAT predisposition in 
immunosuppressed renal transplant recipients.
68 The Ulster Medical Journal
UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).
The Ulster Medical Society grants to all users on the basis of a Creative Commons Attribution-NonCommercial-ShareAlike 
4.0 International Licence the right to alter or build upon the work non-commercially, as long as the author is credited 
and the new creation is licensed under identical terms.
P28. Provision of a genetic testing service for five rare diseases in the Irish Traveller population: ‘The story so far’
Michael Sweeney1, Brónagh o hIcí1, Ania Feder, David E. Barton1,2, Jill Casey2, SallyAnn Lynch1,3, Shirley McQuaid1
1Dept. of Clinical Genetics (DCG), Our Lady’s Children’s Hospital, Crumlin, Dublin 12. 2School of Medicine & Medical Science, University 
College Dublin, Dublin 4, 3Children’s University Hospital, Temple St., Dublin 1
The Irish Traveller community has a high incidence of autosomal recessive (AR) disorders due to consanguinity. The Division of Molecular 
Genetics at the DCG offers genetic testing, primarily to members of this community, for five specific pathogenic mutations found in five AR 
disorders. The pathogenic mutations are detected by bi-directional Sanger sequencing and the service includes:
Gene Disorder/ Disease Phenotype
LARS 
(leucyl-tRNA synthetase)
Infantile Liver Failure Syndrome 1 
(ILFS1) Infantile hepatopathy with failure to thrive (FTT) and developmental delay.
MCM4 (minichromosome 
maintenance 4)
Natural Killer Cell & Glucocorticoid 
Deficiency with DNA Repair Defect 
(NKGCD)
FTT, adrenocorticotropin hormone (ACTH) resistance, familial glucocorticoid 
deficiency (FGD), mosaic Fanconi anaemia and recurrent infections due to NK 
cell deficiency.
STRA6 (stimulated by 
retinoic acid 6 gene)
Autosomal recessive isolated 
colobomatous microanopthalmia 
(MCOPS9)
Microphthalmia, anophthalmia, coloboma. 
Specific STRA6 mutation can also cause the Matthew-Wood syndrome 
[anophthalmia/ severe microphthalmia, with pulmonary hypoplasia/ aplasia]
LEPRE1 (Leucine- 
and proline-enriched 
proteoglycan 1)
syn. PH31(prolyl-3-
hydroxylase-1)
Type VIII Osteogenesis Imperfecta, Variable phenoptype of bone fragility, susceptibility to fracture, short stature, bowing of the long bones and can be perinatally lethal.
ATP8B1 (ATPase, Class I, 
Type 8B, Member1) 
Progressive Familial Intrahepatic 
Cholestasis type 1 (PFIC1) syn. Byler 
disease
Hepatic and systemic accumulation of bile acids, hepatic fibrosis, end-stage 
liver disease and growth retardation.
This study will detail (1) the service offered to users, (2) an audit of the test requests received over the last two years, (3) the challenges 
encountered in offering this unique service and (4) some interesting family pedigrees.
P29 The role of miR-210 in Prostate Cancer tumour development
N McElhatton, CP Walsh, DJ McKenna
Genomic Medicine Research Group, Biomedical Sciences Research 
Institute, Ulster University, Coleraine, BT52 1SA.
Background: Hypoxia in prostate tumours has been linked with 
promotion of disease progression and metastasis. miR-210 is 
a microRNA which is apparently affected by hypoxia, but this 
relationship has not been extensively studied in a prostate cancer 
setting. Therefore, in this study, we investigate the link between 
hypoxia and miR-210 in prostate cancer cells.
Methods: We have used 2D and 3D cell prostate cell models of 
hypoxia to investigate the functionality of miR-210. Expression 
levels of miR-210 have been measured by qPCR and functional 
bioassays used to examine its effect on prostate cell behaviour. 
Target genes have been identified and bioinformatic analysis has 
been employed to investigate a clinical significance for miR-210 in 
prostate cancer.
Results: miR-210 is induced by hypoxia in prostate cancer cell-
lines. Over-expression of miR-210 impacts upon target genes, 
including SP1 and TPD52, which in turns affects cell proliferation. 
Data-mining of online repositories of clinical data and bioinformatic 
analysis of miR-210 cellular networks reveal that miR-210 plays a 
key role in a number of important cell processes, the dysregulation 
of which can lead to development of prostate cancer.
Conclusions: We propose that miR-210 could be an important 
microRNA in the pathogenesis of prostate cancer and has potential 
as a biomarker in this disease.
